PROQUAD

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, New Zealand, Poland, Singapore, Turkey, United States, South Africa

Active ingredients

The drug PROQUAD contains a combination of these active pharmaceutical ingredients (APIs):

1 Measles, live attenuated UNII MFZ8I7277D - MEASLES VIRUS STRAIN ENDERS' ATTENUATED EDMONSTON LIVE ANTIGEN

Read about Measles, live attenuated

2 Mumps, live attenuated UNII 47QB6MX9KU - MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN

Read about Mumps, live attenuated

3 Rubella, live attenuated UNII 52202H034Z - RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN

Rubella virus vaccine contains live attenuated rubella virus, produced in human diploid (MRC-5) cells. It is a virus vaccine for active immunization against rubella that is subcutaneously administered. Read about Rubella, live attenuated

4 Varicella, live attenuated UNII GPV39ZGD8C - VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN

Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity. Read about Varicella, live attenuated

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PROQUAD Powder and solvent for suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BD54	Measles, combinations with mumps, rubella and varicella, live attenuated	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BD Measles vaccines
Discover more medicines within J07BD54

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 525517080020004
Country: CA	Health Products and Food Branch	Identifier(s): 02399229
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 52-MBE-0416
Country: EE	Ravimiamet	Identifier(s): 1243628, 1243639, 1243640, 1243651, 1243662
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 05323010
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 117303
Country: HK	Department of Health Drug Office	Identifier(s): 54831
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7893
Country: IT	Agenzia del Farmaco	Identifier(s): 036893016, 036893028, 036893030, 036893042, 036893055, 036893067, 036893079, 036893081, 036893093, 036893105, 036893117, 036893129, 036893131
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1030464, 1030465, 1030466, 1030467, 1030468, 1030469, 1030470, 1030471, 1030472, 1030473, 1030474, 1091078, 1091079
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11900
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100348562
Country: SG	Health Sciences Authority	Identifier(s): 13563P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699636960400
Country: US	FDA, National Drug Code	Identifier(s): 0006-4171
Country: ZA	Health Products Regulatory Authority	Identifier(s): 49/30.2/1069